The AACE/ACE 2017 recommendations on lipid management renew focus on LDL-C targets, and go far lower than any group has ventured to date.
Veronica Hackenthal, MD
Post-hoc analysis of ACCORD trial data suggests the indication of beta blocker therapy in T2DM patients be more closely examined.
Artificial beta cell systems and insulin pumps went head-to-head in two trials with type 1 diabetes patients.
A new study turns conventional beliefs about metformin’s main site of action upside down.
Three new studies provide evidence to help convince your patients about the importance of healthy eating.
“In brief, the risk for T2DM is a combination of both person and place, and our national strategies need to understand and intervene across these levels.”